Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany.
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany.
J Neuroimmunol. 2014 Sep 15;274(1-2):38-45. doi: 10.1016/j.jneuroim.2014.06.012. Epub 2014 Jun 24.
Laquinimod is an immunomodulatory drug with neuroprotective potential. We used the animal model of experimental autoimmune neuritis (EAN) in the Lewis rat to study the effects of laquinimod treatment. After immunization with the neuritogenic peptide aa 53-78 of P2 myelin protein, preventive therapy with 12.5mg/kg laquinimod once daily inhibited neuritis in clinical and electrophysiological terms. Histology corroborated a lower degree of inflammatory lesions and demyelination in the sciatic nerve. The proportion of FoxP3-positive regulatory T cells in the peripheral lymph nodes of treated rats remained unchanged. We conclude that laquinimod may represent a therapeutic option in human autoimmune neuropathies.
拉喹莫德是一种具有神经保护潜力的免疫调节药物。我们使用实验性自身免疫性神经炎（EAN）的动物模型在 Lewis 大鼠中研究了拉喹莫德治疗的效果。在用 P2 髓鞘蛋白的神经原性肽 aa 53-78 免疫接种后，每天一次给予 12.5mg/kg 拉喹莫德的预防性治疗在临床和电生理方面抑制神经炎。组织学证实坐骨神经中的炎症病变和脱髓鞘程度较低。治疗大鼠外周淋巴结中 FoxP3 阳性调节性 T 细胞的比例保持不变。我们得出结论，拉喹莫德可能是人类自身免疫性神经病变的一种治疗选择。
